How can policy-makers ensure that we benefit from the health developments brought by genomics while satisfying both the expectations of society and the economic imperatives? This book offers a critique of the new governance agenda for science and innovation in the context of the life sciences, and particularly genomics. The authors argue that the governance of genomics presents policy-makers worldwide with a variety of new problems - their valuable research here offers the solutions.